Recent Quotes
View Full List
My Watchlist
Galaxy Digital Holdings
Edit Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Incyte Corporation - Common Stock
(NQ:
INCY
)
120.39
+3.59 (+3.07%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Incyte Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
INCY Q3 deep dive: product diversification accelerates as R&D spending weighs on margins
October 30, 2026
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 14% year on yea...
Via
StockStory
Incyte (INCY) Q3 2026 Earnings Call Transcript
↗
October 29, 2026
Revenue grew 14% as core business surged 30%, with guidance raised on Opzelura momentum.
Via
The Motley Fool
Topics
Earnings
What Incyte (INCY) Said on Its Q3 Earnings Call
↗
October 29, 2026
Incyte (NASDAQ:INCY) reported third-quarter revenue of $1.56 billion, up 14% from a year earlier, as growth in its dermatology and hematology-oncology products helped offset a more modest increase in...
Via
MarketBeat
Topics
Earnings
Incyte (NASDAQ:INCY) Q3 Beat Overshadowed by Below-Consensus Sales Guidance
↗
October 29, 2026
Via
Chartmill
Discover the top S&P500 movers in Monday's after-hours session.
↗
October 12, 2026
Via
Chartmill
Incyte (NASDAQ:INCY) Combines High Growth Momentum With a Breakout Setup
↗
September 30, 2026
Via
Chartmill
Incyte (NASDAQ:INCY) Combines Minervini Trend Template Strength With High-Growth Momentum
↗
September 18, 2026
Via
Chartmill
Incyte’s (NASDAQ:INCY) Q3 2026 sales beat estimates but full-year sales guidance misses expectations significantly
October 29, 2026
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q3 2026, with revenue up 14% year on year ...
Via
StockStory
Topics
Earnings
Incyte (INCY) reports Q3: everything you need to know ahead of earnings
October 27, 2026
Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) will be reporting results this Thursday before market open. Here’s what to look for. Incyte beat a...
Via
StockStory
Topics
Artificial Intelligence
Incyte Highlights Promising Early Data for ’890 and ’734 in GI Cancers
↗
October 26, 2026
Incyte (NASDAQ:INCY) presented updated clinical data and development plans for two experimental solid-tumor programs at ESMO in Madrid: INCA33890, a TGFβR2-by-PD-1 bispecific antibody known as “’890,”...
Via
MarketBeat
2 High-Flying Stocks with Competitive Advantages and 1 We Question
October 16, 2026
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo...
Via
StockStory
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
↗
September 08, 2026
Via
Chartmill
Incyte (NASDAQ:INCY) Passes Minervini Trend and High-Growth Screens, But Setup Demands Patience
↗
August 27, 2026
Via
Chartmill
Incyte (NASDAQ:INCY) Combines High Growth Momentum with a Breakout Setup
↗
August 17, 2026
Via
Chartmill
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
September 30, 2026
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f...
Via
StockStory
Topics
Artificial Intelligence
Discover the top S&P500 movers in Tuesday's pre-market session.
↗
September 22, 2026
Via
Chartmill
Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target
↗
September 19, 2026
Incyte (NASDAQ:INCY) executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after...
Via
MarketBeat
3 Growth Stocks to Add to Your Roster
September 17, 2026
Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...
Via
StockStory
Topics
Economy
Incyte (NASDAQ:INCY): High Growth Stock Slides on Q2 Beat but Steep Guidance Cut
↗
July 28, 2026
Via
Chartmill
1 Cash-Heavy Stock for Long-Term Investors and 2 We Ignore
September 16, 2026
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion o...
Via
StockStory
Topics
Credit Cards
Incyte (INCY): 3 Reasons We Love This Stock
September 14, 2026
Incyte’s 29% return over the past six months has outpaced the S&P 500 by 15.7%, and its stock price has climbed to $119.95 per share. This was partly thanks ...
Via
StockStory
Topics
Artificial Intelligence
Stocks
Here's How Much $1000 Invested In Incyte 20 Years Ago Would Be Worth Today
↗
September 11, 2026
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.25% on an annualized basis producing an average annual return of 17.44%. Currently, Incyte has a market capitalization of...
Via
Benzinga
2 Cash-Producing Stocks with Promising Prospects and 1 We Brush Off
September 11, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Luc...
Via
StockStory
3 Market-Beating Stocks with Competitive Advantages
September 09, 2026
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Via
StockStory
Topics
Artificial Intelligence
Intellectual Property
2 Profitable Stocks with Impressive Fundamentals and 1 We Brush Off
September 04, 2026
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest ...
Via
StockStory
Here’s How Much You Would Have Made Owning Incyte Stock In The Last 20 Years
↗
August 20, 2026
Incyte (NASDAQ:INCY) has outperformed the market over the past 20 years by 8.29% on an annualized basis producing an average annual return of 17.52%. Currently, Incyte has a market capitalization of...
Via
Benzinga
1 Unpopular Stock That Deserves Some Love and 2 Facing Headwinds
July 31, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via
StockStory
Topics
Supply Chain
Exploring the top movers within the S&P500 index during today's session.
↗
July 28, 2026
Via
Chartmill
Curious about which S&P500 stocks are generating unusual volume on Tuesday? Find out below.
↗
July 28, 2026
Via
Chartmill
Incyte Q2 Earnings Call Highlights
↗
July 28, 2026
Incyte (NASDAQ:INCY) reported second-quarter 2026 net product sales of $1.49 billion, up 40% from a year earlier, supported by demand growth across its marketed portfolio and a one-time non-cash...
Via
MarketBeat
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
...
20
21
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
